Primary Hyperoxaluria
Conditions
Keywords
hyperoxaluria, PH, oxalate
Brief summary
The main purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
Interventions
BIOLOGICALOxalobacter formigenes
NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
DRUGPlacebo
placebo
Sponsors
OxThera
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subject (or legally acceptable representative) must give written informed consent (and assent for subjects ≥ 12 years or country specific age as appropriate). For subjects less than 18 years of age, parent or guardian will provide informed consent and the subject will provide witnessed verbal assent 2. Male or female subjects ≥ 5 years of age 3. Urinary oxalate excretion of \> 1.0 mmol/1.73m2/day at Baseline 4. Documentation of diagnosis of PH I or PH II by any one of the following: 1. Liver biopsy confirmation of deficient liver specific peroxisomal alanine-glyoxylate aminotransferase, (AGT) or mislocalization of AGT from peroxisomes to mitochondria (PH I) or deficient glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity (PH II) 2. Homozygosity or compound heterozygosity for a known mutation in the causative genes for PH I and PH II 3. Increased glycolate excretion for PH I or increased L-glycerate excretion for PH II 5. Subjects receiving pyridoxine must be receiving a stable dose for at least 3 months prior to entry in to the study and must remain on the stable dose during the study. Other (non-pyridoxine naïve) subjects (e.g. Pyridoxine non-responder: \<30% reduction of the urine oxalate levels) not receiving pyridoxine at study entry must be willing to refrain from initiating pyridoxine during study participation. Note: There will be no pyridoxine-naïve subjects enrolled in the study. 6. Renal function defined as an estimated GFR ≥ 50 ml/min normalized to 1.73m2 body surface area
Exclusion criteria
1. Pregnant, lactating, or actively menstruating women and women of child-bearing potential who are not using adequate contraceptive precautions. Sexually active females, unless surgically sterile or at least 2 years post-menopausal, must be using a highly effective contraception (including oral, transdermal, injectable, or implanted contraceptives, IUD, abstinence, use of a condom by the sexual partner, or sterile sexual partner) for 30 days prior to the first dose of OxabactTM and must agree to continue using such precautions during the clinical study. Note: A highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomised partner. 2. Positive serum pregnancy test. 3. Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to randomization or not willing to forego other forms of investigational treatment during this study. 4. Subjects on hemodialysis or peritoneal dialysis. 5. Subjects who have undergone transplantation (solid organ or bone marrow). 6. Chronic gastrointestinal disease associated with enteric hyperoxaluria, e.g. history of inflammatory bowel disease, colostomy. Note: For clarity, existence of Secondary Hyperoxaluria (e.g. with cystic fibrosis, chronic inflammatory bowel diseases, short bowel syndrome and/or deficiency of intestinal oxalate-degrading bacteria is included (as an
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in urinary oxalate Percentage change in urinary oxalate (expressed as mmole/1.73m2 /day) from Baseline to Week 24 | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Percentage change in urinary oxalate (expressed as molar oxalate to creatinine ratio) from Baseline to Week 24 | 24 weeks |
| Percentage change in urinary oxalate (expressed as mmole/1.73m2/day and as molar oxalate to creatinine ratio) from Baseline to Week 12 | 12 weeks |
| Percentage of subjects who are responders at Week 24 where response is defined as a 20% or greater reduction from Baseline urinary oxalate to Week 24 | 24 weeks |
| Frequency of AEs and SAEs | over 24 weeks |
| Laborator safety data | 12 and 24 weeks |
| Percentage change in urinary oxalate (expressed as mmole/1.73m2/day and as molar oxalate to creatinine ratio) from Baseline to average of Weeks 12 and 24 | 12 and 24 weeks |
Countries
United States
Outcome results
None listed